Slide 1: Q2 2022 Results Call
| a KemPharm Q2 2022 Results Call August 11, 2022 Trademarks herein are held by their respective owners.
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, includin
Slide 3: Q2 2022 Results Call Agenda
Q2 2022 Results Call Agenda 1) Introduction Travis Mickle, Ph.D. President and Chief Executive Officer 2) AZSTARYS® Update Perry Sternberg President and Chief Executive Officer, Corium, Inc 3) Product Development Updates Travis Mickle 4) Financial Update R. LaDuane Clifton, CPA Chief Financial Offic
Slide 4: AZSTARYS®
AZSTARYS® d-Methylphenidate Prodrug Product for the Treatment of ADHD
Slide 5: Corium, Inc. - AZSTARYS Commercialization
Corium, Inc. —- AZSTARYS® Commercialization End-to-End Pharma Company v Developing and commercializing innovative CNS therapies v Owned by affiliate of Gurnet Point Capital v Offices and manufacturing facility in Grand Rapids, MI and Boston, MA ADHD Expertise v Led by Perry Sternberg and team with b
Slide 6: AZSTARYS Product Overview
AZSTARYS® Product Overview Approved by the U.S. FDA in March 2021 + Indicated for the treatment of ADHD in patients 6 years of age and older + Contains 70% prodrug of d-MPH (serdexmethylphenidate, or SDX) co-formulated with 30% immediate release d-MPH, + Productis a Schedule Il drug, with SDX compon
Slide 7: AZSTARYS - U.S. Commercial Launch Update
AZSTARYS® - U.S. Commercial Launch Update + Steady growth in prescriptions during market introduction phase in both breadth and depth of prescribing + Increasing number of pharmacies ordering AZSTARYS based on geographic areas in which Corium places sales representatives Rx Growth + Initial regional
Slide 8: KemPharm company overview
KEMPH Innovative pharma company with a proven regulatory track record targeting rare CNS, neurodegenerative and lysosomal storage diseases
Slide 9: KemPharm: Q2 2022 and Recent Highlights
KemPharm: Q2 2022 and Recent Highlights v NDA-stage asset expands pipeline targeting rare orphan CNS diseases v “Capital efficient” deal structure w/potential for positive cash flow, and no shareholder dilution v Potential to re-file NDA as early as Q1 2023 Arimoclomol Acquisition v KP1077 IND for I
Slide 10: Product Development Updates
Product Development Updates
Slide 11: Arimoclomol - Expanding Pipeline Targeting Rare Diseases
Arimoclomol - Expanding Pipeline Targeting Rare Diseases Aligns with strategy to build value through the development and commercialization of novel treatments for rare diseases Niemann-Pick disease type C High Upside Opportunity v Ultra-rare progressive, disabling Y NDA-stage investigational drug an
Slide 12: Near-Term Opportunity to Commercialize and Retain Full Market Value
Near-Term Opportunity to Commercialize and Retain Full Market Value Typically, ultra-rare disease commercial teams are less (1) than 20 individuals which can be expanded as additional Arimoclomol represents piddters aré-approved an opportunity for 4 Lower marketing spend since population is well def
Slide 13: KP1077 - Product Candidate Overview
KP1077 — Product Candidate Overview KemPharm is advancing KP1077 as a potential therapeutic treatment for Idiopathic Serdexmethylphenidate ¥ 100% SDX with multiple dosing options v SDX has already been designated C-IV by DEA Regulatory & IP Advantages v Eligible for Fast-Track, Orphan Drug and Break
Slide 14: Upcoming Clinical and Regulatory Milestones Create Potential Near-Term Value
Upcoming Clinical and Regulatory Milestones Create Potential Near-Term Value Milestone Q2 2022 Q3 2022 2022 Q12023. «22023. Q32023 2023 Arimoclomol Re-file NDA for NPC [ KP1077 for IH Type B meeting with FDA IND filing/may proceed Phase 1 CV differentiation trial Phase 2 trial KP1077 for Narcolepsy
Slide 15: Financial Update and Upcoming Milestones
Financial Update and Upcoming Milestones
Slide 16: Financial Position is a Source of Strength
Financial Position is a Source of Strength Q2 2022 Income Statement Details: + Net revenue of $1.3M, derived from arimoclomol product sales under the French EAP, consulting services fees and royalties * Q2 2022 net loss attributable to common stockholders of ($24.0M), or ($0.70) per basic and dilute
Slide 17: KemPharm
ee | a KemPharm Addressing Rare CNS, Neurodegenerative and Lysosomal Storage Diseases For additional information please contact: Jason Rando jrando@tiberend.com